首页> 外文期刊>International Orthopaedics >Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials.
【24h】

Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials.

机译:选择性COX-2抑制剂与非选择性COX-1和COX-2抑制剂在预防全髋关节置换术后异位骨化中的作用:一项随机试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Whether selective cyclo-oxygenase-2 (COX-2) inhibitors are equally effective compared to nonselective NSAIDs for the prevention of heterotopic ossification (HO) after total hip arthroplasty (THA) is still unclear. We carried out a comprehensive search strategy, in which only randomised controlled trials were included. Two reviewers independently assessed methodological quality and extracted outcome data. Analyses were performed using Stata version 10.0. Four eligible randomised controlled trials totalling 808 patients were included. Meta-analysis results showed that no statistically significant difference was found in overall incidence of HO (RR 1.08; 95% CI 0.71-1.64), incidence of moderate severe HO (Brooker II and III) (RR 0.83; 95% CI 0.48-1.42) and any grade of Brooker classification between two groups. In summary, the selective COX-2 inhibitors are equally effective as nonselective NSAIDs for the prevention of HO after THA. Considering the gastrointestinal side effects of nonselective NSAIDs, we recommend selective COX-2 inhibitors for the prevention of HO after THA. However, future well-designed, randomised controlled trials are still needed to further confirm our results.
机译:与非选择性NSAID相比,选择性环加氧酶2(COX-2)抑制剂在预防全髋关节置换术(THA)后异位骨化(HO)方面是否同样有效尚不清楚。我们执行了一项全面的搜索策略,其中仅包括随机对照试验。两名审稿人独立评估方法学质量并提取结果数据。使用Stata 10.0版进行分析。纳入四项合格的随机对照试验,共808例患者。荟萃分析结果显示,HO的总发生率(RR 1.08; 95%CI 0.71-1.64),中度重度HO(Brooker II和III)的发生率(RR 0.83; 95%CI 0.48-1.42)差异无统计学意义。 )以及两组之间的任何等级的布鲁克分类。总之,选择性COX-2抑制剂与非选择性NSAIDs在预防THA后发生HO方面同样有效。考虑到非选择性NSAID的胃肠道副作用,我们建议使用选择性COX-2抑制剂预防THA后的HO。但是,仍需要未来设计良好的随机对照试验来进一步证实我们的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号